Vitamin D: More Than a "Bone-a-Fide" Hormone
Amelia L. M. Sutton and
Paul N. MacDonald
Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio 44106
Address all correspondence and requests for reprints to: Paul N. MacDonald, Ph.D., Department of Pharmacology, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, Ohio 44106. E-mail: pnm2{at}po.cwru.edu.
 |
ABSTRACT
|
---|
The vitamin D endocrine system is critical for the proper development and maintenance of mineral ion homeostasis and skeletal integrity. Beyond these classical roles, recent evidence suggests that the bioactive metabolite of vitamin D, 1,25-dihydroxyvitamin D3, functions in diverse physiological processes, such as hair follicle cycling, blood pressure regulation, and mammary gland development. This minireview explores the current progress in unraveling the complexities of the vitamin D endocrine system by focusing on four main areas of research: the resolution of the vitamin D receptor crystal structure, the molecular details of 1,25-dihydroxyvitamin D3-mediated transcription, murine knockout models of key genes in the endocrine system, and alternative vitamin D receptors and ligands.
 |
INTRODUCTION
|
---|
VITAMIN D WAS discovered nearly a century ago as the nutrient that prevented rickets, a devastating skeletal disease characterized by undermineralized bones (1). Since that time, our concept of vitamin D and, in particular, its most bioactive derivative, 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3], has evolved from that of an essential micronutrient to that of a hormone involved in a complex endocrine system that directs mineral homeostasis, protects skeletal integrity, and modulates cell growth and differentiation in a diverse array of tissues. 1,25-(OH)2D3 acts in concert with PTH to tightly regulate the concentration of serum calcium and phosphate, thereby maintaining proper skeletal mineralization (Fig. 1
). A major function of 1,25-(OH)2D3 is to promote intestinal absorption of calcium and phosphate. However, it also may have direct effects on the bone (2), in which continuous remodeling must occur to sustain structural integrity. For example, in vitro studies indicate that 1,25-(OH)2D3 stimulates osteoblasts, the resident bone-forming cells, to terminally differentiate and to deposit calcified matrix (3). Conversely, when dietary sources are inadequate to maintain normocalcemia, 1,25-(OH)2D3 may stimulate calcium mobilization from the bone by promoting the differentiation of precursor cells into mature, bone-resorbing osteoclasts (4).

View larger version (36K):
[in this window]
[in a new window]
|
Figure 1. Metabolism and Mineral Homeostatic Functions of the Vitamin D Endocrine System
Bioactive 1,25-(OH)2D3 is generated by sequential hydroxylations of its precursor vitamin D3 in the liver and the kidney. 1,25-(OH)2D3 operates in a negative feedback loop by inducing expression of the catabolic enzyme 24-OHase and by inhibiting expression of the anabolic enzyme 1 OHase. In response to low serum calcium, PTH is produced and stimulates 1 OHase expression in the kidney and promotes calcium mobilization from the bone and reabsorption from the kidney. 1,25-(OH)2D3, in turn, induces calcium absorption in the intestine and calcium release from the skeleton.
|
|
The hormonal or bioactive form of vitamin D is 1,25-(OH)2D3. It is generated from sequential hydroxylations of vitamin D3, a secosteroid precursor that is obtained from the diet or produced in the skin upon exposure to UV light (5, 6). The first hydroxylation of vitamin D3 occurs at the C-25 position and is catalyzed by vitamin D-25-hydroxylase in the liver to produce 25-hydroxyvitamin D3 [25(OH)D3], the major circulating form of vitamin D in mammals. 25(OH)D3 is the substrate for a second hydroxylase, the renal 25(OH)D3-1
-hydroxylase (1
OHase), resulting in the production of the most bioactive metabolite, 1,25-(OH)2D3. A classic endocrine feedback system operates to tightly control serum levels of 1,25-(OH)2D3 (5, 6). For example, renal 1
OHase activity is stimulated by low serum calcium and phosphorus levels and by PTH. The expression of 1
OHase is negatively regulated by high levels of 1,25-(OH)2D3. Inactivation, or catabolism, of vitamin D metabolites is initiated by the ubiquitous enzyme 25-hydroxyvitamin D3-24-hydroxylase (24OHase) to generate either 24,25(OH)2D3 or 1,24,25(OH)3D3. The 24-hydroxylated metabolites are further degraded and eventually excreted as either calcitroic acid or 23-carboxyl derivatives. This catabolic process is also carefully regulated as 1,25-(OH)2D3 stimulates 24OHase expression to prevent excessive synthesis of the hormone.
The biological effects of 1,25-(OH)2D3 are mediated through the vitamin D receptor (VDR), a member of the nuclear receptor superfamily of ligand-activated transcription factors (7, 8). Binding of 1,25-(OH)2D3 to VDR initiates a cascade of macromolecular interactions ultimately leading to transcription of select target genes (9). 1,25-(OH)2D3 associates with the VDR and promotes its heterodimerization with retinoid X receptor (RXR), a common heterodimeric partner for other class II nuclear receptors (10). The liganded VDR-RXR heterodimer is the functionally active transcription factor in 1,25-(OH)2D3-mediated transcription. The heterodimer binds with high affinity to vitamin D response elements (VDREs) in the promoters of target genes. VDREs are characterized by two direct hexameric repeats with an intervening spacer of three nucleotides (DR-3 elements). Thus, 1,25-(OH)2D3 target gene selectivity is conferred, in part, through ligand binding, VDR-RXR heterodimerization, and high-affinity binding to DR-3 VDREs. Beyond these initial steps, the precise molecular mechanisms involved in target gene activation by VDR are less evident. Recent attention has turned to so-called coactivator proteins that interact directly with VDR and other nuclear receptors in a ligand-dependent manner (11). These coactivators participate in an intricate multiprotein complex together with the basal transcriptional machinery and histone modifiers to stimulate expression of 1,25-(OH)2D3-regulated genes.
Over the past five years, remarkable strides have been made in clarifying the physiological functions and the concomitant therapeutic potential of vitamin D and its derivatives. Structural studies provide new insight into the ligand-binding pocket of VDR complexed to 1,25-(OH)2D3 and several potent synthetic analogs and, thereby, present a scaffold on which to build future VDR-targeted therapies. A more complete molecular picture of VDR-mediated transcription is emerging as the details of coactivator action are unraveled. Murine knockout models of VDR as well as key enzymes involved in vitamin D metabolism reveal the essential roles of vitamin D in vivo. Finally, investigators have begun to identify novel ligands and alternative VDRs, from synthetic analogs to potential membrane receptors, that signal new directions for the field. Although the range of recent advances extends far, we chose to focus this minireview on these four areas of vitamin D research. Together, these areas of progress have not only affirmed classic paradigms in vitamin D physiology, but they also have opened up new avenues of exploration for future research.
 |
VDR CRYSTAL STRUCTURE
|
---|
The VDR shares discrete structural and functional domains with other nuclear receptors, but it also exhibits several unique features (Fig. 2A
and Refs. 5 and 9). The hypervariable amino-terminal A/B domain of VDR is unusually short and, in contrast to that of most other nuclear receptors, is generally thought to lack potent transactivation domains. However, as discussed later (see VDR Isoforms), there is increasing evidence that the VDR A/B domain helps determine the overall transactivation capacity of the VDR (12). The DNA-binding domain (DBD, or region C) of VDR is similar to that of other nuclear receptors and is characterized by two zinc-binding modules that direct sequence-specific binding of receptors to DNA (13). The ligand-binding domain (LBD, or region E) is a multifunctional globular domain that mediates selective interactions of the receptor with its cognate hormone (13), with other nuclear receptor partners (14), and with comodulatory or adapter proteins (15). The LBD contains the ligand-dependent activation function-2 (AF-2), which is crucial to ligand-activated transcription. Mutation of the AF-2 renders the nuclear receptor transcriptionally inactive despite retaining the ability to bind ligand (14, 15, 16). The DBD and LBD are bridged by the hinge region (domain D), which is thought to confer rotational flexibility between the DBD and LBD and allow for receptor dimerization and interaction with the DNA (17).

View larger version (31K):
[in this window]
[in a new window]
|
Figure 2. Domain Structure of VDR and Two-Step Model of VDR-Mediated Transcription
A, Functional domains of VDR. A/B, Amino-terminal region; DBD, DBD showing two zinc finger modules (Zn); LBD, LBD including the long insertion domain and helix 12 encompassing AF-2. B, Temporal association of coactivators during VDR-mediated transcription. The liganded (D) VDR-RXR heterodimer recruits SRCs and CBP/p300, resulting in acetylation (Ac) of histones. The open chromatin template allows for binding of the DRIP complex and entry of the core transcriptional machinery.
|
|
Although detailed crystal structures for several nuclear receptors have been available for nearly a decade (18, 19, 20, 21, 22), the structure of the VDR LBD was not solved until recently (23). Numerous attempts to crystallize VDR failed, likely due to the presence of a unique insertion sequence in the LBD (see Fig. 2A
) that is largely unordered, leading to decreased protein solubility. Removal of this insertion domain allowed for efficient crystallization and structure determination of the VDR LBD complexed to 1,25-(OH)2D3 (23). Although the lack of this domain may compromise the interpretation of the VDR structure, the mutant VDR displays normal ligand binding and similar transactivation properties in vitro (24). Thus, the absence of the insertion sequence does not alter the conformation significantly so as to compromise VDR function.
The structure of the VDR LBD is similar to that of other nuclear receptors, being most closely related to that of the retinoic acid receptor (RAR)
LBD (23). The VDR LBD is organized into 13
-helices and 3 ß-sheets, which together form a hydrophobic ligand-binding pocket. This pocket is larger than that of RAR
due to variations in the positions of helices H2 and H3n and the H6H7 loop. Helix 12, containing the ligand-dependent AF-2, of ligand-bound VDR is positioned similarly to other nuclear receptors (20), highlighting its central importance in creating a coactivator interaction surface (see VDR Coactivators). In fact, several residues of H12 directly contact the ligand, indicating that the ligand conformation may modulate H12 conformation and, therefore, coactivator binding and transcriptional activity. When additional structures of liganded VDR complexed with various coactivators are solved, they will likely provide a molecular framework on which to develop new compounds to modulate the vitamin D endocrine system.
In this regard, numerous synthetic analogs have already been developed that mimic the advantageous effects of 1,25-(OH)2D3 without the hypercalcemic side effects (see Novel Vitamin D Ligands). Speculation about the mechanisms behind the selective, pleiotropic effects of 1,25-(OH)2D3 analogs centers on the concept that these analogs induce distinct conformations in VDR compared with that of the natural ligand, ultimately resulting in analog-selective gene regulation (25, 26). Protease digestions and coactivator binding studies provide experimental support for this model (25, 27). However, the VDR ligand-binding cavity is larger than that of many other nuclear receptors, and the ligand occupies less than half of this volume. Consequently, the VDR ligand-binding pocket can accommodate rather significant structural changes in the ligand including 1,25-(OH)2D3 analogs with bulky side chains (23, 28). Indeed, the crystal structures of VDR complexed with the MC1288 and KH1060 analogs show that these low calcemic analogs do not induce different conformations in the VDR compared with the natural ligand (29). Thus, other mechanisms must be considered to explain the different potencies and calcemic profiles of the analogs. One potential answer resides in the observation that the VDR-analog complexes are more energetically stable than the VDR-1,25-(OH)2D3 complex (29). The increased half-life of the activated VDR may result in altered transcriptional activity, which may explain the differences both in potencies and in target gene selectivity between the natural and synthetic ligands. Alternatively, the solid-state crystal structure may not reveal subtle dynamic conformational changes in solubilized VDR evoked by various analogs.
 |
VDR COACTIVATORS
|
---|
The existence of limiting accessory factors or adapter proteins in steroid hormone receptor action was proposed in the late 1980s based on the "squelching" phenomenon, in which the LBD of one receptor interferes with ligand-activated transcription mediated by a second receptor (30). A decade later, these comodulatory proteins were identified as specific molecules that interact with nuclear receptors and influence their transactivation potential (31, 32, 33). The emergence of coactivators, and their inhibitory counterparts corepressors, provides new insight into the molecular mechanism of nuclear receptor-mediated transcription. Upon association with its cognate hormone, the receptor LBD undergoes a subtle conformational change (34). The critical change occurs in helix 12, the carboxy-terminal
-helix containing the ligand-dependent AF-2. In response to ligand binding, helix 12 folds over top of the globular LBD and caps the ligand-binding cavity (20). This ligand-dependent conformational shift creates a hydrophobic cleft composed of helices 3, 4, 5, and 12 (35, 36, 37). The hydrophobic cleft serves as a docking surface for many nuclear receptor coactivators by interacting with a complementary hydrophobic domain in the coactivator containing the consensus LXXLL motif, also referred to as the nuclear receptor box (38). Although these studies provide an elegant structural model for ligand-activated transcription by nuclear receptors and LXXLL-containing coactivators, the precise mechanisms governing nuclear receptor-mediated transactivation are less clear. The ability of coactivators to interact with components of the preinitiation complex, with other transcription factors, and with histone-modifying proteins implies that a complex integration of transactivator cues occurs at the promoter of nuclear receptor target genes. The growing number of coactivators identified in the last decade adds yet another level of complexity to the paradigm of nuclear receptor-mediated transcription. Extensive reviews on comodulatory proteins can be found elsewhere (39, 40, 41). Here, we will highlight a few significant developments in the VDR coactivator field.
Steroid receptor coactivator (SRC)-1 [or nuclear receptor coactivator (NCoA)1] is the founding member of the LXXLL motif-containing SRC family of coactivators (33). This family also includes transcriptional intermediary factor-2 (TIF2; Refs. 42 and 43) and receptor-associated coactivator-3 (44, 45, 46, 47, 48). The SRCs interact with VDR and potentiate its transcriptional activity (15, 49). Each of the SRCs possess an autonomous transcriptional activation domain, as evidenced by their ability to enhance transcription when fused to a heterologous DNA-binding sequence such as GAL4. SRCs stimulate transcription possibly by recruiting other transcription factors to the promoter. For example, SRCs interact with cAMP response element binding protein (CBP)/p300, a histone acetyltransferase (HAT) that remodels chromatin structure at the promoter (46, 47, 50). SRCs also possess intrinsic HAT activity (51). CBP/p300 directly associates with nuclear receptors and, together with SRCs, synergistically stimulates transcription (52, 53). Thus, SRCs directly alter chromatin structure and recruit other factors that modify histones, potentially providing more accessible promoter templates on which the transcriptional machinery assembles and initiates transcription of target genes.
A large multiprotein complex called DRIP (VDR-interacting proteins) was identified as a coactivator for VDR and other nuclear receptors (54, 55). Many components of this complex were discovered separately as thyroid receptor activating protein (TRAP) and the mammalian Mediator complex (56, 57). The diversity of transactivator interactions with the DRIP/TRAP/Mediator complex clearly suggests a more fundamental role for this complex in stimulus-activated transcriptional processes. In VDR-mediated transcription, DRIP205/TRAP220 acts as an anchoring subunit of the complex by interacting directly with VDR/RXR heterodimers through one of two LXXLL motifs (58). Biochemical depletion of DRIP in cell-free transcription assays shows that DRIP is essential for VDR-activated transcription in vitro (54). Because the DRIP complex does not contain SRCs and is not associated with HAT activity (58), it is likely that DRIP and SRCs potentiate the transcriptional activation of VDR through distinct mechanisms. Chromatin immunoprecipitations studies indicate that a coactivator exchange occurs in the transcriptional complex on native nuclear receptor-responsive promoters (59, 60, 61). Specifically, SRCs appear to enter the transcriptional complex first and dissociate followed by binding of the DRIP multimeric complex (60, 61). DRIP is also known to recruit the RNA polymerase II holoenzyme to VDR upon ligand binding (62). Although these data conflict, to some extent, with previous studies that show simultaneous association of SRCs and DRIP with activated nuclear receptor complexes (59), they do suggest a temporal model in which SRCs enter the complex first to remodel the chromatin, followed by DRIP complex entry and subsequent recruitment of RNA polymerase II (Fig. 2B
).
In addition to DRIP and SRCs, several other proteins that potentiate VDR-mediated transcription have been described. One example is NCoA-62/ski-interacting protein (SKIP), which is a coactivator unrelated to DRIPs, SRCs, and other LXXLL-containing coactivators (63). It interacts with VDR and other nuclear receptors and augments their transcriptional activity. Bx42, the Drosophila melanogaster ortholog of NCoA-62/SKIP, is also implicated in transcriptional processes activated by the insect steroid ecdysone (64). NCoA-62/SKIP was identified independently through its interaction with ski, placing it as part of the TGF-ß-dependent Smad transcriptional complex (65). It is also implicated in a number of other transcriptional pathways. NCoA-62/SKIP lacks LXXLL motifs and selectively associates with the VDR-RXR heterodimer through the LBD, but through a domain that is distinct from the H3-H5/H12 interactions surface (66). NCoA-62/SKIP binds VDR simultaneously with SRC-1 to form a ternary complex that synergistically enhances VDR-stimulated transcription (66), suggesting a potential interplay between different coactivator classes for maximal activity. Recently, NCoA-62/SKIP was identified in subcomplexes of the spliceosome (67, 68). This, combined with NCoA62/SKIPs ability to contact varied transcription factors including the VDR, suggests a potentially important role for this and other coactivators in coupling nuclear receptor-mediated transcription with mRNA splicing (69).
Although a variety of coactivator proteins have been identified for VDR and other nuclear receptors, their physiological significance and their discrete and/or redundant functions in different signal-activated transcriptional systems remain unclear. Mice with individual targeted deletions of the three SRCs have been developed (70, 71, 72). These models show that the SRCs share several similar functions, especially in the development and maintenance of the female reproductive system. However, the individual SRCs also serve distinct physiological roles. For example, ablation of TIF2/glucocorticoid receptor-interacting protein 1 results in testicular defects, whereas deletion of either SRC-1 or receptor-associated coactivator 3 does not affect male reproduction (71). As the effect of these deletions on 1,25-(OH)2D3-mediated transcription has not been reported in any of these three knockout models, the in vivo relevance of SRCs in VDR-activated transcription remains to be determined. Deletion of the receptor-interacting subunit of the DRIP complex, DRIP205/TRAP220, results in attenuated thyroid hormone-stimulated transcription but does not affect retinoic acid responses. Again, 1,25-(OH)2D3 responses have not been examined in this model, so it is unknown whether DRIP is required for VDR-activated transcription in vivo. Silencing of the Caenorhabditis elegans ortholog of NCoA-62/SKIP by RNA interference results in early embryonic lethality due to a potential general transcription defect (73). Although delineation of the physiological function of NCoA-62/SKIP awaits development of a mammalian knockout model, these data suggest that NCoA-62/SKIP plays a fundamental role in RNA polymerase II-mediated transcription. More studies are needed to build an integrative vision of how the entire ensemble of coactivator proteins associates and stimulates the transcriptional activity of VDR and other nuclear receptors. Initial forays into deciphering this complex process have begun with the application of chromatin immunoprecipitation assays and in vivo imaging of fluorescently tagged nuclear receptors and coactivators to assess the temporal assembly of transcription factors and nuclear receptors on native promoters (59, 60, 61, 74, 75). These strategies, combined with in vitro systems composed of purified components and chromatin-packaged templates, will be required for a more complete understanding of the molecular details of VDR-activated transcription.
 |
KNOCKOUT MODELS
|
---|
Much of our understanding of the physiology of the vitamin D endocrine system has stemmed from classic dietary manipulations and from the analysis of inherited disorders in humans (Ref. 76 and reviewed in Ref. 77). The recent development of murine genetic models in which key genes in this endocrine system have been systematically eliminated highlights the essential role of 1,25-(OH)2D3 in maintaining mineral homeostasis as well as reveals more subtle actions of this hormone in other physiological processes.
VDR Knockout (VDRKO) Mice
Two groups independently created mouse strains with targeted deletions in the VDR gene by disrupting either exon 2 (78) or exon 3 (79). Not surprisingly, the VDRKO mice displayed all of the features of the human disease hereditary vitamin D-resistant rickets (HVDRR), a rare genetic disorder caused by mutations in the VDR gene (Ref. 76 and reviewed in Ref. 77). The VDRKO mice are viable and develop normally until the weaning period. However, shortly after weaning, VDR-null mice exhibit alopecia and growth retardation accompanied by progressive hypocalcemia, hypophosphatemia, and compensatory hyperparathyroidism. These metabolic imbalances result in severe skeletal defects, including decreased bone mineral density, thinned bone cortex, and widened undermineralized growth plates. However, when VDRKO mice are fed a rescue diet rich in calcium and phosphorus to normalize serum calcium and PTH levels, the mice develop normally without bone abnormalities (80). The skeletons of these mice appear grossly, histologically, and biometrically normal (81). This indicates that the bone defect in VDR-null mice is secondary to the malabsorption of calcium in the intestine and is not due to the lack of a direct effect of 1,25-(OH)2D3 on the bone. The impaired intestinal absorption of calcium in the VDRKO mice is linked to diminished intestinal expression of several 1,25-(OH)2D3-regulated genes putatively involved in calcium transport, including calbindin D9K, calcium transport protein-1, and epithelial calcium channel (82, 83). In addition to the intestinal defect in calcium absorption, mice that express a mutant VDR that lacks the DBD have decreased renal reabsorption of calcium (84). These studies reinforce the concept that both the intestine and the kidney are essential VDR target organs in maintaining calcium homeostasis.
The lack of a skeletal phenotype in the VDRKO mice weaned onto the rescue diet is somewhat surprising in light of the vast literature supporting direct, primary roles of VDR in both osteoblast and osteoclast biology (85). On the surface, the VDRKO studies indicate that 1,25-(OH)2D3 is not essential for normal bone development and for maintaining skeletal integrity beyond its classic role in calcium and phosphate absorption in the intestine. However, a standard caveat with gene disruption is that the developing animal may acquire adaptive mechanisms or utilize redundant compensatory pathways to bypass the effects of the gene deletion. Conditional knockout approaches that ablate VDR in a temporally controlled or tissue-specific manner may be more informative. Such strategies could be designed to explore the role of VDR at stage-selective checkpoints in skeletal maturation, at which the possibility of developing compensatory mechanisms has been minimized. Finally, the skeletal phenotypes of normocalcemic VDRKO mice may be more pronounced at different life stages or under different physiological stresses. Thus, it will be important to determine whether normocalcemic VDRKO mice are more susceptible to age-related or ovariectomy-induced loss of bone mineral density and whether they are compromised in their ability to repair skeletal fractures.
In contrast to the skeletal phenotype, the mineral-rich diet does not correct the alopecia (i.e. the absence of functional hair follicles) observed in VDRKO mice (80). Although the VDRKO keratinocytes proliferate and differentiate normally, they fail to properly initiate hair regrowth after depilation (86, 87). Due to the lack of feedback regulation of the anabolic 1
OHase enzyme and the catabolic 24OHase, the VDRKO animals have abnormally high levels of 1,25-(OH)2D3. Thus, one potential cause of alopecia in VDRKO animals is 1,25-(OH)2D3 toxicity. To address this possibility, VDRKO mice were raised and bred for five generations in a UV light-free environment and on a diet lacking vitamin D derivatives (87). Despite having undetectable levels of 1,25-(OH)2D3, fifth-generation vitamin D-deficient VDRKO mice still have alopecia. Thus, 1,25-(OH)2D3 toxicity does not cause alopecia in VDRKO mice. Because wild-type littermates of VDRKO mice raised under the same vitamin D-deficient conditions do not display alopecia, Demay and colleagues (87) proposed that VDR may regulate hair follicle cycling in a ligand-independent fashion. Further support for this hypothesis comes from the observation that mice with a targeted deletion in 25(OH)D3-1
-OHase (see below), the biosynthetic enzyme that produces 1,25-(OH)2D3, do not display alopecia (88). In vitro studies indicate that VDR associates with various transcription factors and induces select genes in the absence of ligand (63, 89, 90, 91). Alternatively, unliganded VDR may repress a subset of target genes in a manner analogous to other nuclear receptors through corepressor interactions (92, 93, 94). Such VDR-RXR-repressed genes could be involved in negatively regulating hair follicle cycling. Although these studies introduce a novel and potentially significant concept in VDR biology, identifying target genes and establishing molecular mechanisms that govern the function of unliganded VDR in keratinocytes are important goals for future research.
The global tissue distribution of VDR suggests that 1,25-(OH)2D3 plays important roles in physiological processes beyond mineral homeostasis and keratinocyte function. For example, VDRKO mice have impaired reproductive function (78). Both male and female VDR-null mice exhibit diminished estradiol levels and elevated gonadotropins, indicating a gonadal dysfunction in the secretion of sex hormones (95). Histological analysis of reproductive glands shows abnormal ovarian follicle development in the females and dilated seminiferous tubules with diminished spermatogenesis in the males. However, serum calcium normalization with the rescue diet mostly corrects the hormonal imbalances and histological abnormalities (95) and completely restores fertility (95, 96), suggesting that the gonadal dysfunction in VDRKO mice primarily results from hypocalcemia.
Mammary gland development is also emerging as a biological process that is impacted by 1,25-(OH)2D3. The mammary glands of VDRKO mice demonstrate a hyperproliferative phenotype as evidenced by increased numbers of terminal end buds and enhanced ductal branching compared with wild-type littermates (97). VDRKO mammary glands also show accelerated ductal development and increased proliferation in response to exogenously administered estrogen and progesterone (97). Although dietary calcium supplementation normalizes estrogen levels in VDRKO mice, the abnormal mammary phenotype is retained. These data indicate a significant developmental role for VDR in the mammary gland potentially in restricting ductal growth. Combined with the observations that 1,25-(OH)2D3 and its analogs inhibit the growth and induce the differentiation of breast cancer cell lines (98, 99), the mammary phenotype in the VDRKO model indicates that 1,25-(OH)2D3 and its derivatives may be useful therapies for breast cancer.
An important immunomodulatory function for 1,25-(OH)2D3 and VDR has been indicated by decades of in vitro studies. For example, 1,25-(OH)2D3 potently inhibits proliferation and drives the differentiation of leukemic cells along the monocyte/macrophage lineage (100). However, VDRKO mice lack a striking immune system phenotype. Although OKelly et al. (101) observed that VDRKO mice have abnormal T cell responses due to diminished cytokine production by macrophages, the calcium-rich rescue diet was not tested in this study. Thus, it is not known whether these abnormalities can be attributed to a lack VDR, to 1,25-(OH)2D3 toxicity, or to hypocalcemia. Mathieu et al. (102) found that VDRKO mice had a defect in calcium-dependent T cell proliferation resulting in protection from experimentally induced autoimmune diabetes and that these abnormalities could be corrected by restoring serum calcium to normal levels. The normal development of the immune system in the VDRKO mice suggests that VDR is not essential for immune function or that other compensatory pathways exist.
Several clinical studies have proposed that 1,25-(OH)2D3 may also be beneficial to the cardiovascular system by decreasing blood pressure (103, 104). Consistent with these observations in humans, VDRKO mice have increased renin expression, resulting in higher levels of angiotensin II, increased water intake, electrolyte disturbances, elevated blood pressure, and cardiac hypertrophy (105). Furthermore, high levels of renin and angiotensin II persist despite normalization of mineral ion levels with the rescue diet. This response appears to be at the transcriptional level, as 1,25-(OH)2D3 suppresses renin promoter activity. This study suggests that VDR negatively regulates the expression of renin, allowing for decreased angiotensin production and lower blood pressure. The relevance of this study to human hypertension is not entirely clear because there are no reports of hypertensive HVDRR patients. Regardless, these are provocative observations in the VDRKO model that may stimulate a more extensive examination of 1,25-(OH)2D3 and its synthetic analogs as potential therapies for some forms of hypertension.
VDR/RXR Double Knockout
VDR heterodimerizes with RXR to modulate transcription of target genes in response to 1,25-(OH)2D3. To examine the effect of abolishing both of the active partners in 1,25-(OH)2D3 signaling, Yagishita and colleagues (106) crossed VDRKO mice with RXR
-null mice to generate VDR/RXR
-double-knockout mice. The phenotype of the double-knockout mice is nearly identical with that of the single-VDR-knockout mouse, including growth retardation, hypocalcemia, hypophosphatemia, hyperparathyroidism, rickets, and alopecia. Upon closer inspection, however, a unique abnormality was noted in the growth plates of long bones of VDR/RXR
-knockout mice that is not present in either of the single-knockout mice. Specifically, VDR/RXR
-null mice have a defect in the development of hypertrophic chondrocytes, the most mature type of chondrocyte in the growth plate. Normalization of serum calcium and phosphorus rescues all of the skeletal anomalies except for the disordered growth plates. Because this chondrocyte defect is not present in either of the single-knockout strains, the authors suggested that a functionally redundant VDR-related receptor exists that selectively heterodimerizes with RXR
. Such a receptor would likely share a considerable amount of sequence similarity with the classical VDR because it must 1) bind to and be transcriptionally activated by 1,25-(OH)2D3 or its metabolites; 2) heterodimerize with RXR
; and 3) recognize and stimulate transcription of the same target genes as classical VDR in chondrocytes. Although the public genome databases do not indicate that highly related sequences exist, potential candidates might include the most closely related nuclear receptors, such as farnesoid X receptor, steroid xenobiotic receptor/pregnane X receptor, and liver X receptor (107). Alternatively, any nuclear receptor unrelated to VDR that selectively heterodimerizes with RXR
and binds 1,25-(OH)2D3 or its metabolites might fulfill this role.
25(OH)D3-1
-Hydroxylase Knockout
Arguably, one of the most significant advances in the vitamin D field over the past five years has been the identification and cloning of the renal 1
OHase, the enzyme responsible for the regulated synthesis of the active hormone (108, 109). To study the effects of the absence of 1,25-(OH)2D3, two groups independently disrupted the 1
OHase gene in mice (88, 110). The phenotype of the 1
OHase-null mice is strikingly similar to that of the VDR-knockout mouse, including hypocalcemia, hyperparathyroidism, growth retardation, and osteomalacia, consistent with rickets (88, 110). The 1
OHase-mutant female mice are anovulatory and, therefore, infertile (88). Another key difference between VDRKO mice and the 1
OHase-ablated mice is that the 1
OHase-knockout animals do not display alopecia (88, 110). The role of hypocalcemia/hypophosphatemia in any aspect of the abnormal phenotype of the 1
OHase-ablated mice has yet to be addressed using the rescue diet. Importantly, the development of knockout models of both the receptor and ligand of 1,25-(OH)2D3 will provide powerful tools to delineate the overlapping and distinct roles of VDR and its ligand in diverse processes such as mineral homeostasis, hair follicle cycling, mammary gland development, and blood pressure regulation.
24OHase Knockout
24OHase metabolizes both the bioactive 1,25-(OH)2D3 and its precursor, 25(OH)D3. 24OHase gene transcription is positively regulated by 1,25-(OH)2D3, thereby completing a negative feedback loop to prevent excessive hormone synthesis. One of the major products of 24OHase, namely 24,25(OH)2D3, is considered to be an inactive metabolite, an initial product destined for further degradation and eventual excretion as calcitroic acid (5). However, there is substantial evidence that 24,25(OH)2D3 has biological activity of its own, most strikingly in the function of chondrocytes, or cartilage-forming cells (111, 112, 113). To determine the consequences of abolishing this enzyme and, therefore, its 24-hydroxylated products, a knockout model of 24OHase was created (114). This mutation results in reduced embryonic viability and aberrant intramembranous ossification. The obvious possibility is that the diminished levels of 24,25(OH)2D3 causes these abnormalities. However, the phenotype is not rescued in 24OHase-knockout progeny by feeding pregnant mice exogenous 24,25(OH)2D3. Alternatively, the phenotype could be caused by the abnormally high levels of 1,25-(OH)2D3 resulting from the deletion of this catabolic enzyme. Indeed, crossing the 24OHase-null mice with VDR-null mice completely rescues the decreased embryonic viability and ossification defects, thus supporting the concept that 1,25-(OH)2D3 toxicity leads to the abnormal phenotype in the 24OHase-knockout mice. Moreover, this model also suggests that 24-hydroxylated metabolites are not required for normal intramembranous ossification (114).
 |
BEYOND 1,25-(OH)2D3 AND VDR: NOVEL LIGANDS AND ALTERNATIVE RECEPTORS
|
---|
Novel Vitamin D Ligands
The therapeutic potential of 1,25-(OH)2D3 continues to expand. In addition to treating disorders of mineral metabolism and diseases of the skeleton, such as rickets, osteoporosis, and renal osteodystrophy, 1,25-(OH)2D3 has significant therapeutic potential for pathologies such as cancer, autoimmune syndromes, and psoriasis. However, 1,25-(OH)2D3 itself has a narrow therapeutic window limited by the development of toxic hypercalcemia. The increase in calcium is achieved both by enhanced intestinal absorption and by liberation of calcium from the skeleton, eventually leading to decreased bone mass at higher doses. This, of course, counteracts the beneficial effects of 1,25-(OH)2D3 for the treatment of bone diseases. Consequently, more than 800 synthetic 1,25-(OH)2D3 analogs have been developed in attempt to preserve the favorable activities of 1,25-(OH)2D3 while avoiding the side effects (115).
Calcipotriol (MC 903) is an analog that has been used to treat psoriasis for nearly 15 yr, and it is currently considered a first-line therapy for the disease (116). Calcipotriol improves psoriasis by inhibiting proliferation and promoting differentiation of keratinocytes, but it does not cause hypercalcemia or decreased bone mass. This selectivity can be attributed to calcipotriols low affinity for vitamin D binding protein, the major vitamin D transport protein in the circulation (117), and the fact that it is applied topically, thus restricting its actions to the skin. 1,25-(OH)2D3 analogs are also valuable in treating renal osteodystrophy, a devastating consequence of chronic renal failure. Kidney disease, due to a variety of causes, often leads to reduced 1,25-(OH)2D3 production and impaired phosphate excretion resulting in abnormally high PTH levels. The decreased calcitriol levels combined with secondary hyperparathyroidism, in turn, result in increased bone turnover (118). Treatment with 1,25-(OH)2D3 is effective in suppressing PTH levels and improving the initial skeletal abnormalities. However, due to the narrow therapeutic window, 1,25-(OH)2D3 often causes hypercalcemia and additional bone disease from inappropriately low bone turnover. Two 1,25-(OH)2D3 analogs are currently approved for treatment of secondary hyperparathyroidism in the United States. 19-Nor-D2 (paricalcitol; Ref. 119) and 1
(OH)D2 (doxercalciferol; Ref. 120) are as effective as 1,25-(OH)2D3 in reducing PTH levels but do not result in significant hypercalcemia. Although the mechanisms of the selectivity of these two analogs remain unclear, they represent significant improvements in treatment regimens for renal osteodystrophy.
Although neither vitamin D3 nor 1,25-(OH)2D3 analogs are currently Food and Drug Administration (FDA)-approved for treating osteoporosis in the United States, these compounds are widely used to prevent and treat osteoporosis throughout the world (121, 122). Furthermore, vitamin D3 is currently recommended as a dietary supplement in addition to any pharmacological treatment for all patients with decreased bone mass or osteoporosis (123). Still, the higher doses of 1,25-(OH)2D3 required for maximal improvement in bone density cause significant hypercalcemia. Peleg and colleagues (124) tested 1,25-(OH)2D3 analogs for their ability to improve bone mineral density in the ovariectomized rat model of osteoporosis. One novel analog, Ro-26-9228, protects against osteopenia, but it does not increase serum calcium except at very high doses. These observations are potentially explained by the tissue-selective action of Ro-26-9228, which stimulates osteocalcin and osteopontin expression in osteoblasts but does not affect calbindin D9K or plasma membrane calcium pump expression in the intestine (124). Shevde et al. (125) found that another analog, 2-methylene-19-nor-(20S)-1
,25(OH)2D3 (2MD), potently stimulates bone formation in vitro and markedly improves bone mass in ovariectomized rats without dramatically increasing serum calcium. Such studies support the concept that more selective 1,25-(OH)2D3 analogs will be useful therapies for osteoporosis by enhancing bone mineral density without causing toxic hypercalcemia.
In addition to these and numerous other designer analogs, a recent study suggests the possibility that natural compounds other than 1,25-(OH)2D3 may serve as tissue-selective activators of VDR-mediated responses. An unexpected ligand for VDR was discovered from studies with bile acid compounds (126). Metabolic lipophilic molecules such as bile acids activate many of the orphan nuclear receptors, including farnesoid X receptor and steroid xenobiotic receptor/pregnane X receptor (127, 128, 129). Recently, Makishima et al. (126) screened classical nuclear receptors to identify those that were activated by the bile acid lithocholic acid (LCA). Surprisingly, they found that LCA and its metabolites directly bind and activate VDR. However, this activation requires micromolar concentrations of LCA, whereas VDR is activated by nanomolar amounts of 1,25-(OH)2D3. Nonetheless, LCA- or 1,25-(OH)2D3-liganded VDR also stimulates the expression of endogenous CYP3A, the P450 enzyme responsible for degradation of LCA in the liver and the intestine. LCA is implicated as a toxin that promotes colorectal carcinogenesis (130, 131), whereas 1,25-(OH)2D3 is protective against colon cancer (132). Thus, induction of CYP3A by 1,25-(OH)2D3 and by LCA itself may represent a detoxification pathway for LCA, as well as explain the potential preventative effects of 1,25-(OH)2D3 in colon cancer. Although this study awaits further in vivo confirmation, it clearly raises the possibility that VDR may be activated by other naturally occurring ligands.
VDR Isoforms
Many nuclear receptors, such as RAR, RXR, and thyroid receptor, have multiple isoforms that are encoded by separate genes (133). Unlike these nuclear receptors, only one human VDR genetic locus has been identified (134), and the genomic database does not indicate additional highly related sequences. Although the cDNA encoding the human VDR was cloned nearly 15 yr ago (8), only recently have several significant variations in the VDR gene, transcript, and protein sequences been discovered. At least 14 distinct transcripts of human VDR have been identified that differ in their 5' ends (135). These transcripts arise from alternative mRNA splicing and differential promoter usage. Most of these variant transcripts utilize the same initiator codon, producing a VDR that is 427 amino acids in length. However, two transcripts have upstream in-frame methionines that potentially generate N-terminal extensions in VDR of 50 or 23 amino acids (135). Low levels of endogenous VDRB1 protein, the 50-amino-acid-extended variant, have been detected in osteoblast, colon cancer, and kidney cell lines (136). Interestingly, VDRB1 has reduced transcriptional activity compared with classical VDR. Whether the levels of expression of these isoforms are substantial and whether these isoforms result in altered biological activity in vivo remains unresolved.
Multiple polymorphic variations also exist in VDR in the human population (137). The vast majority of these polymorphisms do not result in a structural alteration in the VDR protein, with the exception of the Fok I variant (138). The Fok I polymorphism is located at the original initiator ATG, which is part of a Fok I endonuclease site. In some humans, there is an ATG 224 ACG transition at the +1 position, eliminating the translational initiation site and Fok I recognition sequence. This transition results in the use of an in-frame methionine as the initiator codon at the +4 position. Thus, either a 427 (Met-1) or a 424 (Met-4) amino acid protein is expressed. Numerous epidemiological studies suggest an association between the shorter form of VDR and increased bone mineral density in humans (139, 140, 141, 142, 143). The molecular mechanism of this association remains unclear, but there is suggestive evidence that the Met-4 VDR displays enhanced transcriptional activity due to increased interaction with basal transcription factor II B (12). Although these findings remain controversial (144), they raise the possibility that the N terminus possesses some type of structure that influences transcriptional activity. This, combined with the observations that other N-terminal extensions of VDR may have reduced transcriptional activity, suggests that there may be inhibitory domains at the extreme N terminus of VDR that decrease its transactivation potential.
A Membrane Receptor? Rapid, Nongenomic Effects of Vitamin D and Its Metabolites
According to the classical paradigm of nuclear receptor action, ligand-activated nuclear receptors recruit the basal transcriptional machinery and other activator complexes to the promoters of target genes to induce transcription. Because these responses require transcription and translation of target genes, they are typically delayed by at least 30 min. However, more rapid (within seconds to minutes) effects in response to steroid hormones are also apparent. The rapid nature of these effects and their relative insensitivity to transcriptional and translational inhibitors, such as actinomycin D and cycloheximide, precludes the possibility that the traditional "genomic" model is operating. Recent attention to these rapid, "nongenomic" hormone effects has spawned renewed interest in this long-standing area of membrane-initiated signaling in the steroid hormone field (145). Over two decades ago, 1,25-(OH)2D3 was shown to evoke transcellular movement of calcium across chick enterocytes within several minutes (146, 147). This phenomenon is theorized to be adaptively beneficial for a hypocalcemic animal in that rapid absorption of calcium occurs without a delayed response involving transcription and translation of calcium-binding proteins or calcium transporters (147). In addition to the enterocyte, the osteoblast is a target for 1,25-(OH)2D3-induced rapid calcium mobilization from internal stores, a process that involves a membrane-initiated signaling cascade including phospholipase C activation and inositol triphosphate formation (148). This process also occurs in skeletal muscle cells, in which 1,25-(OH)2D3 induces calcium release from the sarcoplasmic reticulum (149), potentially through MAPK activation (150). These are just a few of the many examples of in vitro systems in which these nongenomic actions of 1,25-(OH)2D3 have been studied.
Although the rapid effects of 1,25-(OH)2D3 and numerous other steroids are well documented, the field is hindered by the inability to identify the putative membrane receptors that trigger these nongenomic effects. Although suggestive biochemical and immunological data (151) indicate that the membrane VDR is a distinct gene product, a true protein representing this receptor remains elusive. A promising new approach in the nongenomic field is the use of 1,25-(OH)2D3 analogs to discriminate between receptors that mediate membrane-initiated events and those that mediate the classical nuclear effects of 1,25-(OH)2D3. Song et al. (152) showed that 6-s-cis-locked analogs of 1,25-(OH)2D3 stimulate rapid phosphorylation of MAPK in leukemic cells, yet these analogs bind poorly to VDR and are weak activators of VDR-mediated transcription. These studies also support the possibility of two separate gene products involved in either rapid, nongenomic signaling or in classical transcriptional activation by 1,25-(OH)2D3. In fact, two preliminary reports indicate that annexin II, a membrane-associated calcium-binding protein, may bind 1,25-(OH)2D3 and function as its membrane receptor (153, 154). In contrast to these studies, analysis of mice carrying a mutated VDR lacking a DBD implies that the classical nuclear VDR mediates both genomic and nongenomic responses (84). Osteoblast cultures derived from VDR-mutant mice are unable to initiate a rapid calcium flux in response to 1,25-(OH)2D3, suggesting that some nongenomic responses require a functional nuclear VDR. Although a full array of other nongenomic responses needs to be tested, the VDRKO strains will provide important tools to decipher the molecular requirements of classical VDR that mediate the genomic and nongenomic effects of 1,25-(OH)2D3 in vivo.
 |
SUMMARY: FRONTIERS IN VITAMIN D
|
---|
The molecular, cellular, structural, and genetic studies of the past decade have impacted our understanding of the vitamin D endocrine system in a number of significant ways. First and foremost, the genetic models solidify the fundamental roles that both 1,25-(OH)2D3 and VDR play in ensuring that an organism obtains sufficient calcium and phosphate from the environment to sustain life and normal development. Lack of either functional VDR or active 1,25-(OH)2D3 leads to profound, life-threatening hypocalcemia and undermineralized skeletal tissue. Previous classical nutritional manipulations and identification of mutated VDR as the causative defect in HVDRR have established this central function of 1,25-(OH)2D3 long before the creation of genetic mouse models. However, the development and analysis of such models are central in formulating a detailed physiological picture of 1,25-(OH)2D3 signaling and in reinforcing a direct link between the various genes within the endocrine system and mineral ion dysregulation.
On the other hand, the knockout studies provide somewhat of a surprise and, to a certain extent, a bit of a disappointment for those interested in 1,25-(OH)2D3 and bone biology. In particular, specific cells of the osteoblast and osteoclast lineage have garnered considerable research attention over the past several decades as important direct targets of 1,25-(OH)2D3 in preserving skeletal integrity. However, the striking skeletal defects observed in the VDRKO are corrected by simply providing the animals with supplemental dietary calcium. Does this mean that 1,25-(OH)2D3 does not act as a direct "bone-a-fide" hormone in the skeleton? Clearly, more cellular and genetic approaches are needed to fully answer this question and to test whether VDR and 1,25-(OH)2D3 play more limited or specialized roles in the developing or aging skeleton. Although the jury is still out on the bone, striking new biologies are emerging from the VDRKO studies, indicating potential functions for 1,25-(OH)2D3 in diverse processes such as hair follicle cycling, blood pressure regulation, and mammary gland development that are independent of mineral ion homeostasis. Moreover, studies on alopecia in VDRKO mice raise the exciting possibility that VDR acts in a ligand-independent fashion and may stimulate further exploration into the molecular and cellular functions of unliganded VDR.
Beyond the physiological information gleaned from the genetic mouse models, recent progress in other areas of the vitamin D field is revealing additional molecular details of the endocrine system. Description of the crystal structure of VDR has supplied an atomic view of the VDR protein, highlighting the expansive binding pocket associated with both natural and synthetic ligands. Further refinement of this structure complexed with coactivators undoubtedly will allow for the future rational design of selective VDR-targeted drugs. Some of the additional molecular requirements for the transcriptional activity of 1,25-(OH)2D3-liganded VDR have been elucidated and are beginning to be assembled into an integrated model of coactivator cooperativity. Furthermore, it is becoming increasingly clear that some actions of 1,25-(OH)2D3 cannot be explained by the traditional model of 1,25-(OH)2D3-bound VDR acting solely as a transcription factor in the nucleus. Novel VDR ligands, including synthetic analogs and natural compounds such as bile acids, are broadening our understanding of the therapeutic potential and physiological intricacies of vitamin D. Likewise, alternative receptors, both related to and distinct from the classical nuclear VDR, are emerging as significant participants mediating the biological effects of vitamin D compounds. The four areas of progress covered in this minireview have filled in many gaps in our knowledge of vitamin D, but they also have raised a multitude of new questions that await answering with the new molecular, pharmacological, and genetic tools developed in recent years.
 |
ACKNOWLEDGMENTS
|
---|
We apologize to many colleagues whose excellent primary publications may not have been cited in this minireview due to space limitations.
 |
FOOTNOTES
|
---|
This work was supported by NIH Grants R01-DK-50348 and R01-DK-53980 (to P.N.M.), by an award from the Medical Scientist Training Program NIH Grant T32-GM-007250 (to A.L.M.S.), and by a Pharmaceutical Manufacturers Association Foundation Pre-Doctoral Fellowship (to A.L.M.S.).
Abbreviations: AF-2, Activation function-2; CBP, cAMP response element binding protein-binding protein; DBD, DNA-binding domain; 1,25-(OH)2D3, 1,25-dihydroxyvitamin D3; 1
OHase, 25(OH)D3-1
-hydroxylase; 25-(OH)D3, 25hydroxyvitamin D3; 24-OHase, 25-(OH)D3-24-hydroxylase; DRIP, VDR-interacting protein; HAT, histone acetyltransferase; HVDRR, hereditary vitamin D-resistant rickets; LBD, ligand-binding domain; LCA, lithocholic acid; NCoA, nuclear receptor coactivator; RAR, retinoic acid receptor; RXR, retinoid X receptor; SKIP, ski-interacting protein; SRC, steroid receptor coactivator; TIF2, transcription intermediary factor-2; TRAP, thyroid receptor-activating protein; VDR, vitamin D receptor; VDRE, vitamin D response element; VDRKO, VDR knockout.
Received for publication November 1, 2002.
Accepted for publication March 5, 2003.
 |
REFERENCES
|
---|
- Brown AJ, Dusso A, Slatopolsky E 1999 Vitamin D. Am J Physiol 277:F157F175
- van Leeuwen JP, van Driel M, van den Bemd GJ, Pols HA 2001 Vitamin D control of osteoblast function and bone extracellular matrix mineralization. Crit Rev Eukaryot Gene Expr 11:199226[Medline]
- Owen TA, Aronow MS, Barone LM, Bettencourt B, Stein GS, Lian JB 1991 Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 128:14961504[Abstract]
- Bar-Shavit Z, Teitelbaum SL, Reitsma P, Hall A, Pegg LE, Trial J, Kahn AJ 1983 Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 80:59075911[Abstract]
- Jones G, Strugnell SA, DeLuca HF 1998 Current understanding of the molecular actions of vitamin D. Physiol Rev 78:11931231[Abstract/Free Full Text]
- Horst RL, Reinhardt TA 1997 Vitamin D metabolism. In: Feldman D, Glorieux, FH, Pike JW, eds. Vitamin D. San Diego: Academic Press; 1332
- McDonnell DP, Mangelsdorf DJ, Pike JW, Haussler MR, OMalley BW 1987 Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 235:12141217[Medline]
- Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J, OMalley BW 1988 Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85:32943298[Abstract]
- Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW 1998 The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325349[Medline]
- Mangelsdorf DJ, Evans RM 1995 The RXR heterodimers and orphan receptors. Cell 83:841850[Medline]
- McKenna NJ, Lanz RB, OMalley BW 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20:321344[Abstract/Free Full Text]
- Jurutka PW, Remus LS, Whitfield GK, Thompson PD, Hsieh J-C, Zitzer H, Tavakkoli P, Galligan MA, Dang HTL, Haussler CA, Haussler MR 2000 The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401420[Abstract/Free Full Text]
- McDonnell DP, Scott RA, Kerner SA, OMalley BW, Pike JW 1989 Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. Mol Endocrinol 3:635644[Abstract]
- Nakajima S, Hsieh JC, MacDonald PN, Galligan MA, Haussler CA, Whitfield GK, Haussler MR 1994 The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. Mol Endocrinol 8:159172[Abstract]
- Masuyama H, Brownfield CM, St-Arnaud R, MacDonald PN 1997 Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. Mol Endocrinol 11:15071517[Abstract/Free Full Text]
- Danielian PS, White R, Lees JA, Parker MG 1992 Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors. EMBO J 11:10251033[Abstract]
- Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
- Schwabe JW, Chapman L, Finch JT, Rhodes D 1993 The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75:567578[Medline]
- Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ 1995 A structural role for hormone in the thyroid hormone receptor. Nature 378:690697[CrossRef][Medline]
- Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the RAR-
ligand-binding domain bound to all-trans retinoic acid. Nature 378:681689[CrossRef][Medline]
- Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D 1995 Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-
. Nature 375:377382[CrossRef][Medline]
- Weatherman RV, Fletterick RJ, Scanlan TS 1999 Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 68:559581[CrossRef][Medline]
- Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D 2000 The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173179[Medline]
- Rochel N, Tocchini-Valentini G, Egea PF, Juntunen K, Garnier JM, Vihko P, Moras D 2001 Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur J Biochem 268:971979[Abstract/Free Full Text]
- Peleg S, Sastry M, Collins ED, Bishop JE, Norman AW 1995 Distinct conformational changes induced by 20-epi analogues of 1
,25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 270:1055110558[Abstract/Free Full Text]
- Carlberg C, Quack M, Herdick M, Bury Y, Polly P, Toell A 2001 Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues. Steroids 66:213221[CrossRef][Medline]
- Yang W, Freedman LP 1999 20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. J Biol Chem 274:1683816845[Abstract/Free Full Text]
- Norman AW, Manchand PS, Uskokovic MR, Okamura WH, Takeuchi JA, Bishop JE, Hisatake JI, Koeffler HP, Peleg S 2000 Characterization of a novel analogue of 1
,25(OH)2-vitamin D3 with two side chains: interaction with its nuclear receptor and cellular actions. J Med Chem 43:27192730[CrossRef][Medline]
- Tocchini-Valentini G, Rochel N, Wurtz JM, Mitschler A, Moras D 2001 Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc Natl Acad Sci USA 98:54915496[Abstract/Free Full Text]
- Tasset D, Tora L, Fromental C, Scheer E, Chambon P 1990 Distinct classes of transcriptional activating domains function by different mechanisms. Cell 62:11771187[Medline]
- Cavailles V, Dauvois S, Danielian PS, Parker MG 1994 Interaction of proteins with transcriptionally active estrogen receptors. Proc Natl Acad Sci USA 91:1000910013[Abstract/Free Full Text]
- Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M 1994 Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:14551458[Medline]
- Onate S, Tsai, SY, Tsai, M-J, OMalley, BW 1995 Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:13541357[Abstract]
- Leid M 1994 Ligand-induced alteration of the protease sensitivity of retinoid X receptor
. J Biol Chem 269:1417514181[Abstract/Free Full Text]
- Feng W, Ribeiro RCnJ, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL 1998 Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280:17471749[Abstract/Free Full Text]
- Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV 1998 Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-
. Nature 395:137143[CrossRef][Medline]
- Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927937[Medline]
- Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733736[CrossRef][Medline]
- McKenna NJ, OMalley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465474[Medline]
- McKenna NJ, OMalley BW 2002 Minireview: nuclear receptor coactivatorsan update. Endocrinology 143:24612465[Abstract/Free Full Text]
- Rosenfeld MG, Glass CK 2001 Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 276:3686536868[Free Full Text]
- Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:49484952[Abstract/Free Full Text]
- Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:36673675[Abstract]
- Li H, Gomes PJ, Chen JD 1997 RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:84798484[Abstract/Free Full Text]
- Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965968[Abstract/Free Full Text]
- Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569580[Medline]
- Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677684[CrossRef][Medline]
- Takeshita A, Cardona GR, Koibuchi N, Suen CS, Chin WW 1997 TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 272:2762927634[Abstract/Free Full Text]
- Kraichely DM, Collins 3rd JJ, DeLisle RK, MacDonald PN 1999 The autonomous transactivation domain in helix H3 of the vitamin D receptor is required for transactivation and coactivator interaction. J Biol Chem 274:1435214358[Abstract/Free Full Text]
- Ikeda M, Kawaguchi A, Takeshita A, Chin WW, Endo T, Onaya T 1999 CBP-dependent and independent enhancing activity of steroid receptor coactivator-1 in thyroid hormone receptor-mediated transactivation. Mol Cell Endocrinol 147:103112[CrossRef][Medline]
- Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai MJ, OMalley BW 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194198[CrossRef][Medline]
- Chakravarti D, LaMorte VJ, Nelson MC, Nakajima T, Schulman IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/P300 in nuclear receptor signalling. Nature 383:99103[CrossRef][Medline]
- Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403414[Medline]
- Rachez C, Suldan Z, Ward J, Chang CP, Burakov D, Erdjument-Bromage H, Tempst P, Freedman LP 1998 A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. Genes Dev 12:17871800[Abstract/Free Full Text]
- Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Naar AM, Erdjument-Bromage H, Tempst P, Freedman LP 1999 Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398:824828[CrossRef][Medline]
- Fondell JD, Ge H, Roeder RG 1996 Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. Proc Natl Acad Sci USA 93:83298333[Abstract/Free Full Text]
- Jiang YW, Veschambre P, Erdjument-Bromage H, Tempst P, Conaway JW, Conaway RC, Kornberg RD 1998 Mammalian mediator of transcriptional regulation and its possible role as an end-point of signal transduction pathways. Proc Natl Acad Sci USA 95:85388543[Abstract/Free Full Text]
- Rachez C, Gamble M, Chang CP, Atkins GB, Lazar MA, Freedman LP 2000 The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. Mol Cell Biol 20:27182726[Abstract/Free Full Text]
- Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843852[Medline]
- Burakov D, Crofts LA, Chang CP, Freedman LP 2002 Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor. J Biol Chem 277:1435914362[Abstract/Free Full Text]
- Sharma D, Fondell JD 2002 Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci USA 99:79347939[Abstract/Free Full Text]
- Chiba N, Suldan Z, Freedman LP, Parvin JD 2000 Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme. J Biol Chem 275:1071910722[Abstract/Free Full Text]
- Baudino TA, Kraichely DM, Jefcoat Jr SC, Winchester SK, Partridge NC, MacDonald PN 1998 Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 273:1643416441[Abstract/Free Full Text]
- Wieland C, Mann S, von Besser H, Saumweber H 1992 The Drosophila nuclear protein Bx42, which is found in many puffs on polytene chromosomes, is highly charged. Chromosoma 101:517525[Medline]
- Dahl R, Wani B, Hayman MJ 1998 The Ski oncoprotein interacts with Skip, the human homolog of Drosophila Bx42. Oncogene 16:15791586[CrossRef][Medline]
- Zhang C, Baudino TA, Dowd DR, Tokumaru H, Wang W, MacDonald PN 2001 Ternary complexes and cooperative interplay between NCoA-62/Ski-interacting protein and steroid receptor coactivators in vitamin D receptor-mediated transcription. J Biol Chem 276:4061440620[Abstract/Free Full Text]
- Zhou Z, Licklider LJ, Gygi SP, Reed R 2002 Comprehensive proteomic analysis of the human spliceosome. Nature 419:182185[CrossRef][Medline]
- Makarov EM, Makarova OV, Urlaub H, Gentzel M, Will CL, Wilm M, Luhrmann R 2002 Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science 298:22052208[Abstract/Free Full Text]
- Auboeuf D, Honig A, Berget SM, OMalley BW 2002 Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298:416419[Abstract/Free Full Text]
- Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, OMalley BW 1998 Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:19221925[Abstract/Free Full Text]
- Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P 2002 The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22:59235937[Abstract/Free Full Text]
- Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, OMalley BW 2000 The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:63796384[Abstract/Free Full Text]
- Kostrouchova M, Housa D, Kostrouch Z, Saudek V, Rall JE 2002 SKIP is an indispensable factor for Caenorhabditis elegans development. Proc Natl Acad Sci USA 99:92549259[Abstract/Free Full Text]
- Stenoien DL, Nye AC, Mancini MG, Patel K, Dutertre M, OMalley BW, Smith CL, Belmont AS, Mancini MA 2001 Ligand-mediated assembly and real-time cellular dynamics of estrogen receptor
-coactivator complexes in living cells. Mol Cell Biol 21:44044412[Abstract/Free Full Text]
- Becker M, Baumann C, John S, Walker DA, Vigneron M, McNally JG, Hager GL 194 2002 Dynamic behavior of transcription factors on a natural promoter in living cells. EMBO Rep 3:11881181[Abstract/Free Full Text]
- Hughes MR, Malloy PJ, Kieback DG, Kesterson RA, Pike JW, Feldman D, OMalley BW 1988 Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 242:17021705[Medline]
- Malloy PJ, Pike JW, Feldman D 1999 The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev 20:156188[Abstract/Free Full Text]
- Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, Kawakami T, Arioka K, Sato H, Uchiyama Y, Masushige S, Fukamizu A, Matsumoto T, Kato S 1997 Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 16:391396[Medline]
- Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB 1997 Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94:98319835[Abstract/Free Full Text]
- Li YC, Amling M, Pirro AE, Priemel M, Meuse J, Baron R, Delling G, Demay MB 1998 Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139:43914396[Abstract/Free Full Text]
- Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB 1999 Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140:49824987[Abstract/Free Full Text]
- Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, Bindels RJ, Collen D, Carmeliet P, Bouillon R, Carmeliet G 2001 Duodenal calcium absorption in vitamin D receptor-knockout mice: functional and molecular aspects. Proc Natl Acad Sci USA 98:1332413329[Abstract/Free Full Text]
- Li YC, Bolt MJG, Cao L-P, Sitrin MD 2001 Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism. Am J Physiol Endocrinol Metab 281:E558E564
- Erben RG, Soegiarto DW, Weber K, Zeitz U, Lieberherr M, Gniadecki R, Moller G, Adamski J, Balling R 2002 Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. Mol Endocrinol 16:15241537[Abstract/Free Full Text]
- Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH, Whitfield GK 1997 The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 154:S57S73
- Sakai Y, Demay MB 2000 Evaluation of keratinocyte proliferation and differentiation in vitamin D receptor knockout mice. Endocrinology 141:20432049[Abstract/Free Full Text]
- Sakai Y, Kishimoto J, Demay MB 2001 Metabolic and cellular analysis of alopecia in vitamin D receptor knockout mice. J Clin Invest 107:961966[Abstract/Free Full Text]
- Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D 2001 Targeted ablation of the 25-hydroxyvitamin D 1
-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98:74987503[Abstract/Free Full Text]
- Masuyama H, Jefcoat Jr SC, MacDonald PN 1997 The N-terminal domain of transcription factor IIB is required for direct interaction with the vitamin D receptor and participates in vitamin D-mediated transcription. Mol Endocrinol 11:218228[Abstract/Free Full Text]
- Lavigne AC, Mengus G, Gangloff YG, Wurtz JM, Davidson I 1999 Human TAF(II)55 interacts with the vitamin D(3) and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties. Mol Cell Biol 19:54865494[Abstract/Free Full Text]
- Tolon RM, Castillo AI, Jimenez-Lara AM, Aranda A 2000 Association with Ets-1 causes ligand- and AF2-independent activation of nuclear receptors. Mol Cell Biol 20:87938802[Abstract/Free Full Text]
- Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454457[CrossRef][Medline]
- Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK 1995 Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 377:451454[CrossRef][Medline]
- Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Soderstrom M, Glass CK, Rosenfeld MG 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397404[CrossRef][Medline]
- Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y 2000 Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 141:13171324[Abstract/Free Full Text]
- Johnson LE, DeLuca HF 2001 Vitamin D receptor null mutant mice fed high levels of calcium are fertile. J Nutr 131:17871791[Abstract/Free Full Text]
- Zinser G, Packman K, Welsh J 2002 Vitamin D(3) receptor ablation alters mammary gland morphogenesis. Development 129:30673076[Abstract/Free Full Text]
- Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP 1995 20-Epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55:28222830[Abstract]
- Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP 2000 The anti-proliferative effects of 1
,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:50915097[CrossRef][Medline]
- Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, Suda T 1981 Differentiation of mouse myeloid leukemia cells induced by 1
,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:49904994[Abstract]
- OKelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP 2002 Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 109:10911099[Abstract/Free Full Text]
- Mathieu C, Van Etten E, Gysemans C, Decallonne B, Kato S, Laureys J, Depovere J, Valckx D, Verstuyf A, Bouillon R 2001 In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 16:20572065[Medline]
- Kristal-Boneh E, Froom P, Harari G, Ribak J 1997 Association of calcitriol and blood pressure in normotensive men. Hypertension 30:12891294[Abstract/Free Full Text]
- Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S 1995 Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8:894901[CrossRef][Medline]
- Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P 2002 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229238[Abstract/Free Full Text]
- Yagishita N, Yamamoto Y, Yoshizawa T, Sekine K, Uematsu Y, Murayama H, Nagai Y, Krezel W, Chambon P, Matsumoto T, Kato S 2001 Aberrant growth plate development in VDR/RXR
double null mutant mice. Endocrinology 142:53325341[Abstract/Free Full Text]
- Whitfield GK, Jurutka PW, Haussler CA, Haussler MR 1999 Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. J Cell Biochem (Suppl)3233:110122
- Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S 1997 25-Hydroxyvitamin D3 1
-hydroxylase and vitamin D synthesis. Science 277:18271830[Abstract/Free Full Text]
- St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH 1997 The 25-hydroxyvitamin D 1-
-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res 12:15521559[Medline]
- Dardenne O, Prudhomme J, Arabian A, Glorieux FH, St-Arnaud R 2001 Targeted inactivation of the 25-hydroxyvitamin D3-1
-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology 142:31353141[Abstract/Free Full Text]
- Seo E-G, Einhorn TA, Norman AW 1997 24R,25-Dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 138:38643872[Abstract/Free Full Text]
- Seo EG, Norman AW 1997 Three-fold induction of renal 25-hydroxyvitamin D324-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture. J Bone Miner Res 12:598606[Medline]
- Boyan BD, Sylvia VL, Dean DD, Schwartz Z 2001 24,25-(OH)2D3 regulates cartilage and bone via autocrine and endocrine mechanisms. Steroids 66:363374[CrossRef][Medline]
- St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH 2000 Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141:26582666[Abstract/Free Full Text]
- Brown AJ 2001 Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38:S3S19
- Scott LJ, Dunn CJ, Goa KL 2001 Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2:95120[Medline]
- Bouillon R, Allewaert K, Xiang DZ, Tan BK, van Baelen H 1991 Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 6:10511057[Medline]
- Slatopolsky E, Brown A, Dusso A 1999 Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73:S14S19
- Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J 1998 19-Nor-1-
-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:14271432[Abstract]
- Tan Jr AU, Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW 1997 Effective suppression of parathyroid hormone by 1
hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317323[Medline]
- Tilyard MW, Spears GF, Thomson J, Dovey S 1992 Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 326:357362[Abstract]
- Ikeda K, Ogata E 2000 Modulation of bone remodeling by active vitamin D: its role in the treatment of osteoporosis. Mech Ageing Dev 116:103111[CrossRef][Medline]
- 2000 Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 17:145
- Peleg S, Uskokovic M, Ahene A, Vickery B, Avnur Z 2002 Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats. Endocrinology 143:16251636[Abstract/Free Full Text]
- Shevde NK, Plum LA, Clagett-Dame M, Yamamoto H, Pike JW, DeLuca HF 2002 A potent analog of 1
,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci USA 99:1348713491[Abstract/Free Full Text]
- Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ 2002 Vitamin D receptor as an intestinal bile acid sensor. Science 296:13131316[Abstract/Free Full Text]
- Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294:18661870[Abstract/Free Full Text]
- Lu TT, Repa JJ, Mangelsdorf DJ 2001 Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 276:3773537738[Free Full Text]
- Xie W, Evans RM 2001 Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 276:3773937742[Free Full Text]
- Debruyne PR, Bruyneel EA, Karaguni IM, Li X, Flatau G, Muller O, Zimber A, Gespach C, Mareel MM 2002 Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 21:67406750[CrossRef][Medline]
- Kozoni V, Tsioulias G, Shiff S, Rigas B 2000 The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21:9991005[Abstract/Free Full Text]
- Lamprecht SA, Lipkin M 2001 Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann NY Acad Sci 952:7387[Abstract/Free Full Text]
- Aranda A, Pascual A 2001 Nuclear hormone receptors and gene expression. Physiol Rev 81:12691304[Abstract/Free Full Text]
- Miyamoto K-i, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, Pike JW 1997 Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 11:11651179[Abstract/Free Full Text]
- Crofts LA, Hancock MS, Morrison NA, Eisman JA 1998 Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci USA 95:1052910534[Abstract/Free Full Text]
- Sunn KL, Cock TA, Crofts LA, Eisman JA, Gardiner EM 2001 Novel N-terminal variant of human VDR. Mol Endocrinol 15:15991609[Abstract/Free Full Text]
- Wood RJ, Fleet JC 1998 The genetics of osteoporosis: vitamin D receptor polymorphisms. Annu Rev Nutr 18:233258[CrossRef][Medline]
- Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D 1996 The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 11:18501855[Medline]
- Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E 1997 A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 12:915921[Medline]
- Harris SS, Eccleshall TR, Gross C, Dawson-Hughes B, Feldman D 1997 The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J Bone Miner Res 12:10431048[Medline]
- Ferrari S, Rizzoli R, Manen D, Slosman D, Bonjour JP 1998 Vitamin D receptor gene start codon polymorphisms (FokI) and bone mineral density: interaction with age, dietary calcium, and 3'-end region polymorphisms. J Bone Miner Res 13:925930[Medline]
- Gennari L, Becherini L, Mansani R, Masi L, Falchetti A, Morelli A, Colli E, Gonnelli S, Cepollaro C, Brandi ML 1999 FokI polymorphism at translation initiation site of the vitamin D receptor gene predicts bone mineral density and vertebral fractures in postmenopausal Italian women. J Bone Miner Res 14:13791386[Medline]
- Ames SK, Ellis KJ, Gunn SK, Copeland KC, Abrams SA 1999 Vitamin D receptor gene Fok1 polymorphism predicts calcium absorption and bone mineral density in children. J Bone Miner Res 14:740746[Medline]
- Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D 1998 The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res 13:16911699[Medline]
- Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M 2000 Multiple actions of steroid hormonesa focus on rapid, nongenomic effects. Pharmacol Rev 52:513556[Abstract/Free Full Text]
- Nemere I, Yoshimoto Y, Norman AW 1984 Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D3. Endocrinology 115:14761483[Abstract]
- Norman AW 1997 Rapid biological responses mediated by 1
,25-dihydroxyvitamin D3: a case study of transcaltachia (rapid hormonal stimulation of intestinal calcium transport). In: Feldman FHG, Pike JW, eds. Vitamin D. San Diego: Academic Press; 233256
- Le Mellay V, Grosse B, Lieberherr M 1997 Phospholipase Cß and membrane action of calcitriol and estradiol. J Biol Chem 272:1190211907[Abstract/Free Full Text]
- Vazquez G, de Boland AR, Boland RL 1998 1
,25-Dihydroxy-vitamin-D3-induced store-operated Ca2+ influx in skeletal muscle cells. Modulation by phospholipase C, protein kinase C, and tyrosine kinases. J Biol Chem 273:3395433960[Abstract/Free Full Text]
- Morelli S, Buitrago C, Vazquez G, De Boland AR, Boland R 2000 Involvement of tyrosine kinase activity in 1
,25(OH)2-vitamin D3 signal transduction in skeletal muscle cells. J Biol Chem 275:3602136028[Abstract/Free Full Text]
- Nemere I, Ray R, McManus W 2000 Immunochemical studies on the putative plasmalemmal receptor for 1,25(OH)2D3. I. Chick intestine. Am J Physiol Endocrinol Metab 278:E1104E1114
- Song X, Bishop JE, Okamura WH, Norman AW 1998 Stimulation of phosphorylation of mitogen-activated protein kinase by 1
,25-dihydroxyvitamin D3 in promyelocytic NB4 leukemia cells: a structure-function study. Endocrinology 139:457465[Abstract/Free Full Text]
- Baran DT, Quail JM, Ray R, Honeyman T 2000 Binding of 1
,25-dihydroxyvitamin D3 to annexin II: effect of vitamin D metabolites and calcium. J Cell Biochem 80:259265[CrossRef][Medline]
- Baran DT, Quail JM, Ray R, Leszyk J, Honeyman T 2000 Annexin II is the membrane receptor that mediates the rapid actions of 1
,25-dihydroxyvitamin D3. J Cell Biochem 78:3446[CrossRef][Medline]